- Pressemitteilung BoxID 67711
biolitec AG achieved consolidated revenue of Euro 35.4 million for the fiscal year 2007/2008
EBIT amounts to Euro 1.4 million
The gross profit amounted to Euro 23.9 million (last fiscal year: Euro 26.5 million) and EBIT amounted to Euro 1.4 million (previous year:Euro 6.9 million). R&D expenditures for the fiscal year 2007/2008 of Euro 5.1 million (14% of sales) remained at a high level to ensure the groups long term growth and profitability. Net income amounted to Euro 1.98 million (previous year: Euro 5.7 million) despite the continuous high R&D investments as well as the decline in sales.
The revenue posted by the laser segment of Euro 12.1 million was lower than in the prior year mainly due to the market decline in the USA. The fiber optics and laser probes segment contributed € 21.9 million to the group's total revenue (previous year: € 21.7 million).Mainstays of sales are the LIFE(TM) BPH laser treatment and the Endoluminal Laser Treatment of Veins (ELVeS(TM) ).
biolitec's major revenues were again generated in Europe and North America. With Euro 14.7 million, sales in North America were 22%lower than previous year's sales contributing 42% of total sales.European sales amounted to Euro 17.9 million (previous year: Euro 17.8 million).biolitec AG expects sales growth to resume in this fiscal year.
Diese Pressemitteilungen könnten Sie auch interessieren
Sozial- und Integrationsminister Manne Lucha hat Fördermittel des Landes in Höhe von 15,25 Millionen Euro für vorbereitende Baumaßnahmen für...
Im 40. Jahr ihres Bestehens stellt sich die HanseMerkur Reiseversicherung AG (HMR) zum 1. März 2017 auch personell neu auf. Das Unternehmen,...